Transient Interferon-Driven Natural Killer Cell Activation in Acute Hepatitis C - Takeaways - MDSpire

Transient Interferon-Driven Natural Killer Cell Activation in Acute Hepatitis C

  • By

  • Benedikt Strunz

  • Qiuyao Zhan

  • Tanvi Khera

  • Julia Hengst

  • Marija Jankovic

  • Katja Deterding

  • Annika Niehrs

  • Markus Cornberg

  • Cheng-Jian Xu

  • Heiner Wedemeyer

  • Niklas K Björkström

  • the HepNet Acute HCV IV Study Group

  • Christoph D Spinner

  • Eckart Schott

  • Tania M Welzel

  • Guido Gerken

  • Hartwig Klinker

  • Ulrich Spengler

  • Johannes Wiegand

  • Julian Schulze zur Wiesch

  • Anita Pathil

  • Andreas Umgelter

  • Caroline Zöllner

  • Stefan Zeuzem

  • Armin Papkalla

  • Kristina Weber

  • Svenja Hardtke

  • Heiko von der Leyen

  • Armin Koch

  • Dorothee von Witzendorff

  • Michael P Manns

  • Kerstin Port

  • Bernhard Schlevogt

  • Marc Ringelhan

  • Ulrich Mayr

  • Judith Schrewe

  • Katharina Sosnowsky

  • Christoph Jochum

  • Gudrun Hilgard

  • Petra Schulze

  • Susanne Wiebecke

  • Ji-Eun Lee

  • Peter Hoffmann

  • December 29, 2025

  • 0 min

Share

  • 1

    Acute hepatitis C infection can be effectively treated with direct-acting antivirals, contrasting with previous interferon-based therapies.

  • 2

    Natural killer (NK) cells play a crucial role in the immune response during acute hepatitis C infection.

  • 3

    A subset of highly activated NK cells with a type I interferon signature was identified in patients with acute hepatitis C.

  • 4

    The population of activated NK cells diminished after successful viral clearance, indicating reversible immune alterations.

  • 5

    This study enhances understanding of the immunological mechanisms underlying the antiviral response in acute hepatitis C.

Original Source(s)

Transient Interferon-Driven Natural Killer Cell Activation in Acute Hepatitis C

  • by Benedikt Strunz, Qiuyao Zhan, Tanvi Khera, Julia Hengst, Marija Jankovic, Katja Deterding, Annika Niehrs, Markus Cornberg, Cheng-Jian Xu, Heiner Wedemeyer, Niklas K Björkström, the HepNet Acute HCV IV Study Group, Christoph D Spinner, Eckart Schott, Tania M Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Andreas Umgelter, Caroline Zöllner, Stefan Zeuzem, Armin Papkalla, Kristina Weber, Svenja Hardtke, Heiko von der Leyen, Armin Koch, Dorothee von Witzendorff, Michael P Manns, Kerstin Port, Bernhard Schlevogt, Marc Ringelhan, Ulrich Mayr, Judith Schrewe, Katharina Sosnowsky, Christoph Jochum, Gudrun Hilgard, Petra Schulze, Susanne Wiebecke, Ji-Eun Lee, Peter Hoffmann

  • December 29, 2025

Related Content

Co-infection of HIV and HCV Among Patients Under Antiretroviral Treatment: Insights from Selected Healthcare Facilities in Ilorin, Nigeria

Assessment of Liver Cancer Burden from 1990 to 2021 with Projections for 2040: Findings from the 2021 Global Burden of Disease Study

Impact of Viral Infections on Immune Microenvironment Alterations and Responses to Immune Checkpoint Therapy: Interactions Between Infection, Immunity, and Cancer